Rain Therapeutics

Rain Oncology, Inc. is a clinical-stage precision oncology company, which focuses on developing and implement the precision oncology therapies for patients suffering from cancer. The company was founded by Avanish Vellanki and Robert Doebele in April 2017 and is headquartered in Newark, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rain Oncology is a clinical-stage company focusing on research and development of innovative therapies for cancer patients.  Rain Oncology provides a tumor-agnostic strategy to select patients based on tumors’ underlying genetics rather than histology.  Rain Oncology was founded in 2017 and was headquartered in Newark, California.

NEWARK, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced it will report financial results for the first quarter ended March 31, 2022 and highlights of recent progress on Wednesday, May 4, 2022. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company's business and financial results.

Rain Therapeutics to Report First Quarter 2022 Financial Results and Highlights of Recent Progress on May 4, 2022

NEWARK, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced a poster presentation and two trials in progress at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, being held virtually and in New Orleans, Louisiana from April 8-13, 2022.

Rain Therapeutics Announces a Poster Presentation and Trials In Progress at the American Association for Cancer Research (AACR) Annual Meeting 2022

Rain Therapeutics, Inc. (RAIN) CEO Avanish Vellanki on Q4 2021 Results - Earnings Call Transcript

– Quarter-end cash position of $140.2 million provides runway to complete all ongoing and planned clinical trials of milademetan, including an ample cash cushion for the Phase 3 MANTRA trial in liposarcoma –

Rain Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Progress

– Industry veterans from Loxo/Lilly, Gilead, Seagen and AltruBio join Rain to expand clinical and regulatory operations –

Rain Therapeutics Continues to Strengthen its Leadership Team with Key Appointments

NEWARK, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will participate in a fireside chat at the Piper Sandler 33rd Annual Healthcare Conference being held virtually November 29-December 2, 2021 and at the Evercore ISI 4th Annual Health CONx Virtual Conference being held virtually November 30-December 2, 2021.

Rain Therapeutics to Present at Upcoming Investor Conferences

The interventional, multicenter, open-label Phase 2 basket trial will evaluate the safety and efficacy of milademetan in patients with MDM2-amplified advanced solid tumors The interventional, multicenter, open-label Phase 2 basket trial will evaluate the safety and efficacy of milademetan in patients with MDM2-amplified advanced solid tumors

Rain Therapeutics Doses First Patient in Phase 2 Basket Trial of Milademetan for MDM2-Amplified Advanced Solid Tumors (MANTRA-2)

Rain Therapeutics, Inc. (RAIN) CEO Avanish Vellanki on Q3 2021 Results - Earnings Call Transcript

New Phase 2 clinical trial planned for milademetan in Merkel cell carcinoma (MCC), the MANTRA-3 trial, to start in mid-2022

Rain Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Progress

The Merkel cell trial will be prioritized over the previously planned Phase 2 trial in patients with intimal sarcoma, and will evaluate milademetan in patients with IO-refractory disease

Rain Therapeutics Plans Phase 2 Merkel Cell Carcinoma Clinical Trial (MANTRA-3) of Milademetan

NEWARK, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced it will report financial results for the third quarter that ended September 30, 2021 and highlights of recent progress, on Wednesday, November 10, 2021. On that day, management will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss the Company's business and financial results.

Rain Therapeutics to Report Third Quarter 2021 Financial Results and Highlights of Recent Progress on November 10, 2021

Tuesday, November 9th at 11:00 am ET Tuesday, November 9th at 11:00 am ET

Rain Therapeutics Hosting Research and Development (R&D) Day

Presentations highlight potential of the oral MDM2 inhibitor, milademetan, in advanced cancers with MDM2 amplification, GATA3 mutant ER-positive breast cancer, and Merkel cell carcinoma Presentations highlight potential of the oral MDM2 inhibitor, milademetan, in advanced cancers with MDM2 amplification, GATA3 mutant ER-positive breast cancer, and Merkel cell carcinoma

Rain Therapeutics Presents Data on Milademetan (RAIN-32) at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

NEWARK, Calif., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will present at the Cantor Fitzgerald Virtual Global Healthcare Conference being held virtually September 27-30, 2021.

Rain Therapeutics to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

NEWARK, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021.

Rain Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference

Rain Therapeutics, Inc. (RAIN) CEO Avanish Vellanki on Q2 2021 Results - Earnings Call Transcript

First patient dosed in Phase 3 registrational trial (MANTRA) evaluating milademetan (RAIN-32) in patients with dedifferentiated (“DD”) liposarcoma (“LPS”)

Rain Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Progress

NEWARK, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., (NasdaqGS: RAIN) a late-stage company developing precision oncology therapeutics, today announced it will report financial results for the second quarter that ended June 30, 2021 and highlights of recent progress, on Tuesday, August 10, 2021. On that day, management will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss the Company's business and financial results.

Rain Therapeutics to Report Second Quarter 2021 Financial Results and Highlights of Recent Progress on August 10, 2021

Werewolf Therapeutics

In light of the global initial public offering market recording its strongest second quarter in two decades by volume and proceeds, four stocks that had their IPO during the past three months and outperformed the Standard & Poor's 500 index benchmark by at least 10% over the past month are Werewolf Therapeutics Inc. ( HOWL , Financial), Ecit AS ( OSL:ECIT , Financial), Effnetplattformen Holding AB ( OSTO:EFFH , Financial) and Rain Therapeutics Inc. ( RAIN , Financial) according to the All-in-One Screener, a Premium feature of GuruFocus.

4 Global IPO Stocks Outperforming the S&P 500 Over the Past Month

Clinical trial for MDM2-amplified cancers expected to commence in second half of 2021 Clinical trial for MDM2-amplified cancers expected to commence in second half of 2021

Rain Therapeutics Announces Patient Referral Partnership for the Planned MDM2-Amplified Phase 2 Basket Trial of RAIN-32

NEWARK, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”), a clinical-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will present a corporate overview and participate in one-on-one investor meetings at the Goldman Sachs 42nd Annual Global Healthcare Conference taking place virtually from June 8-11, 2021.

Rain Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

The stock price of Rain Therapeutics Inc (NASDAQ: RAIN) increased by 9.39% yesterday. This is why it happened.

RAIN Stock Price: 9.39% Increase Explanation

Completed initial public offering ("IPO") with net proceeds of $121.9 million

Rain Therapeutics Reports First Quarter 2021 Financial Results and Highlights Recent Progress

Dr. Doebele, Rain co-founder, will continue to serve as chief scientific officer Dr. Doebele, Rain co-founder, will continue to serve as chief scientific officer

Rain Therapeutics Appoints Robert Doebele, M.D., Ph.D. as President

Agiliti Inc

Impel Neuropharma

Latham Group

Treace Medical Concepts

Latham Group, Treace Medical Concepts, Impel NeuroPharma, and Rain Therapeutic are on the Nasdaq. Agiliti is on the New York Stock Exchange.

News for Rain Therapeutics Stock (RAIN)